Werewolf Therapeutics, Inc.
$1.04
-3.7%Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -0.5).
Valuation inputs: P/E -0.5, earnings yield N/A, momentum -3.7%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -2.5%, ROIC -1.7%).
Profitability stack: net margin 0.0%, ROE -2.5%, ROIC -1.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +64.3%, momentum -3.7%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Werewolf Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Werewolf Therapeutics, Inc. Fair Value Envelope
Werewolf Therapeutics, Inc. Profit Bridge
Profitability Analysis
Werewolf Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Werewolf Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Strong liquidity. The company has adequate resources to meet short-term liabilities.
Debt-to-Equity Ratio
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Werewolf Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that HOWL stock may see slight declines over the coming 12 months. The consensus 1-year price target stands at 1.00, with estimates ranging from a low of 1.00 to a high of 1.00.
The consensus 1-year price target stands at 1.00, with estimates ranging from a low of 1.00 to a high of 1.00.
Analyst Consensus Analysis
Upside Potential
Fair value territory. Stock trading near consensus target suggests limited near-term catalysts. Focus on fundamental developments.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Risk-Reward Profile
Balanced risk-reward. Upside and downside potential relatively symmetric. Suitable for moderate risk tolerance with conviction in thesis.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Efficient pricing: Stock trading at fair value with strong consensus suggests market has priced in expectations. Look for fundamental inflection points or new catalysts to drive meaningful moves.
Werewolf Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $231K and sold $6.52M worth of HOWL shares, resulting in $6.29M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
891.9K
635.04K
-635K
-$635K
6-9 Months
0
0.00
5.1M
5.89M
-5.9M
-$5.89M
9-12 Months
179.4K
230.83K
0
0.00
+231K
+$231K
Top Buyers
Morrison Briggs
Director
$35K
Lazarus Alon
Director
$35K
Chatterjee Meeta
Director
$35K
Evnin Luke
Director
$35K
Sherman Michael A.
Director
$35K
Top Sellers
Mpm Bioventures 2014, L.P.
Other: Former 10% Owner
$2.22M
Gadicke Ansbert
Other: Former 10% Owner
$2.22M
Evnin Luke
Director
$2.08M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $6.29M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
No Dividend Yield Data
HOWL has not reported any dividend yield values in the available annual periods.
howl Dividend History
Learning Layer
Related Guides
Build conviction on HOWL by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.